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Background: Tumor-associated macrophages (TAMs) are the major component of tumor-infiltrating leukocytes.
TAMs are heterogeneous, with distinct phenotypes influenced by the microenvironment surrounding tumor tissues,
but relatively little is known about the key molecular in these cells that contribute to malignant phenotypes.
Autophagic activity is a critical factor in tumor development that contributes to enhancing cellular fitness and
survival in the hostile tumor microenvironment. However, the molecular basis and relations between autophagy
and TAMs polarization remain unclear.
Methods: Cathepsin S (Cat S) expression was analyzed in human colon carcinoma and normal colon tissues. In vivo
effects were evaluated using PancO2 subcutaneous tumor model and SL4 hepatic metastasis model.
Immunofluorescence staining, flow cytometry and real-time PCR were done to examine TAMs polarization. Western
blotting assay, transmission electron microscopy, mCherry-GFP-LC3 transfection and DQ-BSA degradation assays
were carried out to determine its role in regulating autophagy.
Results: In the present study, we showed that the enhanced expression of Cat S correlated with the severity of
histologic grade as well as clinical stage, metastasis, and recurrence, which are known indicators of a relatively poor
prognosis of human colon carcinoma. Cat S knockout led to decreased tumor growth and metastasis. Moreover,
Cat S knockout inhibited M2 macrophage polarization during tumor development. We further demonstrated that
Cat S was required for not only autophagic flux but also the fusion processes of autophagosomes and lysosomes in
TAMs. Importantly, we found that Cat S contributed to tumor development by regulating the M2 phenotype of
TAMs through the activation of autophagy.
Conclusions: These results indicated that Cat S-mediated autophagic flux is an important mechanism for inducing
M2-type polarization of TAMs, which leads to tumor development. These data provide strong evidence for a
tumor-promoting role of autophagy in TAMs and suggest Cat S could be a potential target for cancer therapy.
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Smouldering inflammation is a component of the tumor
microenvironment, has recently been considered a hall-
mark of cancer with an important role in tumor initi-
ation and progression [1,2]. In tumor microenvironment,
innate immune cells are highly represented, and among
the most abundant of these are macrophages. Although
the original hypotheses proposed that macrophages are
involved in antitumor immunity, there is substantial
clinical and experimental evidence that in the majority
of cases these tumor-associated macrophages (TAMs)
enhance tumor progression to malignancy [3]. TAMs
are heterogeneous in response to environmental signals
and generally exhibit similarities with prototypic polarized
M2 macrophages, contributing to tumor growth, invasion
and angiogenesis [3-5]. Human clinical studies have
shown a role of TAMs as tumor promoters based on
the association of increased density of TAMs with tumor
vascularization, metastasis, and poor prognosis [6-10],
which have served as a paradigm for cancer-related in-
flammation. The link between TAMs and tumor devel-
opment is well established. However, the mechanisms
of TAMs moving toward a tumor-promoting phenotype
are not fully understood.
Autophagy is an evolutionarily conserved, catabolic
process that involves the entrapment of cytoplasmic
components within characteristic vesicles for their delivery
to and degradation within lysosomes [11-13]. The role
of autophagy extends beyond the general homeostatic
removal, degradation, and recycling of damaged pro-
teins and organelles to many specific physiological and
pathological processes such as development, immunity,
energy homeostasis, cell death, tumorigenesis, among
others [14-16]. Autophagy is a multifaceted process, and
alterations in autophagic signaling pathways are fre-
quently found in cancer [17-19]. While the involvement
of autophagy in tumor development is widely accepted,
it remains incompletely understood.
It is generally suggested that endolysosomal proteases
play important roles in the degradation and regulation
events of autophagic processes [11]. Cathepsins are cysteine
lysosomal proteases that are essential for the turnover
of intracellular and extracellular proteins internalized
by endocytosis; cathepsins are now recognized that cyst-
eine proteases play pivotal roles in cancer progression
[20]. Of the cysteine cathepsins, B, L and S have been
implicated most in serving as prognostic markers in
cancer associated with poor outcome [21-25]. Cathepsin
S (Cat S), unlike the ubiquitous cathepsin B (Cat B) and
cathepsin L (Cat L), exhibits a restricted tissue expression.
It is found predominantly in lymphatic tissue, macrophages,
and other antigen-presenting cells [26]. There is an increas-
ing body of data highlighting the upregulation of Cat S in a
spectrum of tumors [23-25,27], where levels of the proteaseincrease with the grade and aggressiveness of disease
[28,29]. Studies previously demonstrated that macrophage-
secreted Cat S plays a key role in tumor progression [30].
Recently, we further elucidated that Cat S deficiency
results in abnormal accumulation of autophagosomes
in macrophages and enhances Angiotensin II–induced car-
diac inflammation [31]. However, whether Cat S-mediated
autophagic flux promotes tumor development via the
induction of TAMs polarization remains unclear. Thus,
understanding the complex catabolic reactions that occur
in the endolysosomal compartment is crucial for eluci-
dating the mechanisms underlying TAMs-mediated
tumor-promoting effects.
In this study, we identified that the expression of Cat
S by TAMs is critical for promoting tumor growth and
metastasis in vivo. We showed that Cat S deletion sig-
nificantly blocked polarizing macrophages to the M2
phenotype within the tumor microenvironment. More-
over, we observed that Cat S deficiency led to the accumu-
lation of autophagosomes and attenuation of autophagic
flux in macrophages within the tumor microenvironment.
Finally, we demonstrated that Cat S-mediated autopha-
gic flux was pivotal to maintain polarization of the M2
TAMs phenotype.
Results
Cat S expression is elevated in human cancer tissue
To determine whether cathepsin levels are increased in
human colon carcinoma, real-time quantitative PCR was
performed to measure the expression of cathepsin family
members in human colon carcinoma and adjacent normal
colon tissues. As shown in Figure 1A, the mRNA levels of
Cat B, Cat L and Cat S were significantly elevated in can-
cer specimens compared with the matched normal tissues.
Especially, analysis by quantitative real-time PCR revealed
Cat S was prominently expressed and highly enriched in
colon carcinoma specimens compared to healthy tissues,
while the mRNA expression of Cat D, Cat F, Cat H, Cat
K or Cat Z was not significant difference between colon
carcinoma and normal colon tissues (Figure 1A). Immu-
nohistochemical staining demonstrated that the expres-
sion of Cat S in adjacent normal colon tissues was low,
whereas Cat S was observed in inflammatory-like cells
located in carcinoma tissues (Figure 1B, left panels). Cat
S expression was significantly elevated in poorly differ-
entiated colon carcinoma, which was markedly higher
than that of moderately differentiated or well differenti-
ated colon carcinoma (Figure 1B, left panels). Moreover,
we observed that Cat S was expressed in a high percentage
of stage III and IV tumors (Figure 1B, right panels). Ana-
lysis of Cat S expression in primary tumors and metastases
formation revealed that patients who had advanced clinical
stage disease, metastasis, or recurrence within 3 years
showed increased Cat S expression in colon cancer tissue
Figure 1 Expression of Cat S in tumor tissues. (A) Quantitative real-time PCR analysis of the mRNA level of Cathepsin family members in
human colon carcinoma and adjacent normal colon tissues (samples from 15 human adenocarcinoma tissues and the healthy adjacent tissue).
GAPDH was a normalization control. **, P<0.01 vs adjacent normal colon tissues. (B) HE staining and immunohistochemical analysis of Cat S or
macrophage marker CD68 expression in normal colon tissues and human colon carcinoma. Histopathological differentiation grade indicates
well-, moderately- and poorly-differentiated. T indicates tumor invasion depth. N indicates lymph node metastasis. M indicates distant
metastasis. (×200 magnification and Scale bars = 100 μm). Quantitative analysis of Cat S expression in tumor sections at different histologic
grade (well, moderate and poor), different tumor stages (I–IV;) and with or without recurrence 3 years after operation (n = 5-10 samples per
group, with 10 fields per samples). **, P<0.01.
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with human colon cancer aggressiveness.
Furthermore, advanced colon carcinoma tissues were
markedly and extensively infiltrated by CD68-positive
macrophages, particularly along the tumor cell-invasive
front, while few macrophages were observed in normal
colon tissues (Figure 1B, left panels). Cat S was expressed
mainly in stromal macrophages as verified by staining with
CD68, demonstrating that Cat S localizes to macrophages
in stromal compartments of solid tumors. Cat S-positive
cells within the area colocalized with CD68-positive
macrophages, indicating a high concordance of CD68 andCat S expression in human primary colon carcinoma
during malignant progression.
Cat S deficiency inhibits tumor growth and metastasis
In order to investigate the roles of Cat S in the tumor
microenvironment, we analyzed the effects of Cat S knock-
out on tumor growth and metastasis using subcutaneous
and metastatic tumor models. In PancO2 subcutaneous
tumor model, we found that Cat S knockout substantially
suppressed tumor volume and reduced tumor weight
(Figure 2A). The average tumor volume in the WT mice
increased to 495.3 ± 73.17 mm3 for 28 days after PancO2
Figure 2 Cat S deficiency inhibits tumor growth and metastasis. (A) Representative images of tumors of WT and Cat S−/− mice 28 days after
subcutaneously inoculation of PancO2 cells. A suspension of 1 × 106 PancO2 cells was injected subcutaneously into the flank of anaesthetized
WT and Cat S−/− mice. Mice were killed 28 days after transplant, and tumors were weighted after dissection. Bar = 1 mm. Data are mean ± SEM
for n = 10 mice **, P<0.01. (B) Immunohistochemical analysis of Ki-67 expression in PancO2 tumor burden into WT and Cat S−/− mice. (×400
magnification and Scale bars = 50 μm). Quantitative analysis of Ki-67 positive cells in tumor sections. Data are mean ± SEM for n = 10 mice with 10
fields per animal. **, P<0.01 vs WT mice. (C) Gross examination of development of liver metastasized tumor of colon cancer after intrasplenic
injection of SL4 cells in WT and Cat S−/− mice. SL4 cells (1 × 106) were injected into the spleen of WT and Cat S−/− mice. Mice were sacrificed at
14 days after tumor injection to determine the incidence of liver metastasis and tumor weight. The normal livers from WT or Cat S−/− mice as
control groups. Data are mean ± SEM for n = 10 mice **, P<0.01. (D) The analysis of micrometastasis was performed on paraffin-embedded
sections with HE staining in metastasized foci after intrasplenic injection of SL4 cells in WT and Cat S−/− mice. Number of micrometastatic lesions
per one representative cross section of the livers from each mouse. (×100 magnification and Scale bars = 100 μm). Data are mean ± SEM for
n = 10 mice with 10 fields per animal. **, P<0.01.
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decreased to 181.0 ± 20.06 mm3, a significant inhibition of
tumor growth (P<0.01). Moreover, immunohistochemistry
showed that Ki-67 expression in PancO2 subcutaneous
tumors was significantly lower in Cat S−/− mice than in
WT mice (Figure 2B). Previous studies have shown that
SL4 cells injected intrasplenically formed tumors in the
livers of mice [32], thus the SL4 cell line is a useful tool to
study the process of tumor metastasis. To investigate therole of Cat S in liver metastasis of colon carcinoma cells,
SL4 cells were injected into the spleens of WT and Cat
S−/− mice.
As shown in Figure 2C, there was no difference in nor-
mal liver weight between WT and Cat S−/− mice. Fourteen
days after SL4 injection, gross inspection demonstrated a
marked increase of liver weight in WT mice due to mul-
tiple hepatic tumor nodules compared with weight of nor-
mal liver, whereas livers from Cat S−/− mice showed fewer
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to that in WT mice (Figure 2C). To further investigate
whether Cat S knockout attenuates tumor metastasis, the
metastatic potential was quantified by scoring micrometas-
tasis to livers in H&E-stained sections. We observed the
number of metastatic foci was markedly decreased in Cat
S−/− mice versus WT mice on HE staining (Figure 2D), in-
dicating a strong suppression in the metastatic potential of
tumor cells. To investigate whether suppressing tumor de-
velopment in Cat S−/− mice could be caused by inhibition
of angiogenesis, the sections were immunostained using
the CD31 antibody (a marker of endothelial cells) to assess
angiogenesis in tumor tissues. As shown in Additional file
1: Figure S1A, immunostaining for endothelial cells (CD31)
demonstrated reduced microvessel density in PancO2 sub-
cutaneous tumor from Cat S−/− mice compared with that
of in WT mice. Consistently, the density of CD31-positive
microvessels from metastasized foci after intrasplenic injec-
tion of SL4 cells was significantly smaller in Cat S−/− mice
than those in WT mice (Additional file 1: Figure S1B).
Therefore, the absence of stroma-derived Cat S inhib-
ited tumor growth, metastasis and angiogenesis, supporting
a tumor-promoting role of infiltrating leukocytes ex-
pressing Cat S.
Cat S deficiency inhibits transition toward the M2
phenotype in TAMs
To further analyze the cellular origin of Cat S expression
in tumor-infiltrating leukocytes, tumor sections were im-
munostained with the macrophage marker Mac-2 to assess
macrophage infiltration into the tumor stroma. Immuno-
histochemical staining demonstrated that the expression of
Mac-2 in hepatic metastatic tumors did not significantly
differ between WT and Cat S−/− mice (Figure 3A and B).
Moreover, Cat S was highly expressed in macrophages,
while Cat S−/− macrophages showed no Cat S expression
(Figure 3C). Furthermore, we did not observe a significant
difference in F4/80-positive cells between WT and Cat S−/−
mice in hepatic metastatic tumors (Figure 3C).
TAMs are prominent components of leukocyte infiltrates
and are frequently polarized to an M2 phenotype, which is
characterized by tumor-promoting properties [4,6,33]. To
further establish whether Cat S is necessary for M2 macro-
phage polarization in the tumor microenvironment, we
assessed the cell surface expression of CD206, a marker of
M2 macrophage. Immunofluorescence analysis revealed
that double-positive F4/80 and CD206 viable macrophages
were abundant in the tumors of WT mice but not in
Cat S−/− mice (Figure 3D). We further analyzed the
macrophage phenotypes in tumors using flow cytometric
analysis. As shown in Figure 3E, the population of macro-
phages (CD45+F4/80+ cells) in hepatic metastatic tumors
of WT mice was predominantly CD206-positive, while the
proportion of CD45+F4/80+CD206+ cells was significantlyreduced in the tumors of Cat S−/− mice (13.99 ± 1.45% ver-
sus 37.09 ± 2.81% for CD45+F4/80+CD206+ cells, P<0.01)
(Figure 3E). These results suggest that Cat S may drive
macrophages toward the M2 phenotype in the tumor
microenvironment.
Cat S deficiency induces autophagosome accumulation
in TAMs
Previous studies showed that autophagy is critical for
malignant progression of tumors, serving to both reduce
oxidative stress and provide key intermediates to sustain
cell metabolism [34,35]. We recently reported that Cat S
deficiency results in abnormal accumulation of autopha-
gosomes in macrophages with angiotensin II treatment
[31]. Therefore, we further analyzed whether the role of
Cat S in the regulation of TAMs polarization was linked
to autophagy. On immunofluorescence staining, we ob-
served colocalization of the autophagosomal marker LC3
and macrophage marker F4/80 in the hepatic metastatic tu-
mors of WT mice, and this effect was markedly increased
in Cat S−/− mice (Figure 4A).
To examine the expression of Cat S in macrophages,
double-color immunofluorescence analysis was performed
in bone marrow-derived macrophages. As shown in
Additional file 2: Figure S2A, Cat S was expressed in
F4/80-positive macrophages. Importantly, the level of
Cat S expression in WT macrophages was markedly el-
evated after coculture with SL4 cells under serum-
starved conditions. Western blotting demonstrated
that SL4 cells significantly increased the level of Cat S
protein in WT macrophages under serum-starved condi-
tions (Additional file 2: Figure S2B). To further confirm the
role of Cat S in vitro, confocal fluorescence microscopy
showed that SL4 cells stimulated LC3 protein clustering in
WT macrophages under serum-starved conditions, which
was further enhanced in Cat S−/− macrophages (Figure 4B).
To investigate whether autophagic structures were
increased in Cat S−/− macrophages in the tumor micro-
environment, we detected autophagic vesicles by transmis-
sion electron microscopy (TEM). Autophagic vesicles
are hallmarked by unique double membranes and by the
presence of engulfed cytosolic content: features that allow
them to be easily detected by TEM. Although WT or Cat
S−/− macrophages contained very few autophagic vesicles
and did not differ in the formation of autophagosomes at
baseline, SL4 cells induced cytosolic autophagic vacuole
formation in serum-starved WT macrophages (Figure 4C).
Especially, many large vesicles containing engulfed and
digested membrane and organelle structures were ob-
served in Cat S−/− macrophages with SL4 cells cocul-
ture (Figure 4C).
The formation of phagophores and autophagosomes is
associated with lipidation of LC3-I with phosphatidyleth-
anolamine to produce the membrane-associated LC3-II
Figure 3 Cat S deficiency reduces M2 macrophage infiltration in tumor development. (A) Immunohistochemical analysis of macrophage
infiltration in metastasized foci after intrasplenic injection of SL4 cells in WT and Cat S−/− mice. Macrophage infiltration detected by anti-Mac-2
immunostaining (×400 magnification and Scale bars = 50 μm). (B) Quantitative analysis of Mac-2 positive cells in metastasized foci sections.
Data are mean ± SEM for n = 8 mice with 10 fields per animal. NS indicates not significant. (C) Double-color immunofluorescence analysis of
macrophage and Cat S expression in metastasized foci from WT and Cat S−/− mice. The sections were immunostained with anti-F4/80 and
anti-Cat S antibodies. (×400 magnification and Scale bars = 50 μm). (D) Double-color immunofluorescence analysis of M2 macrophage
expression in metastatic foci from WT and Cat S−/− mice. The sections were immunostained using the combination of anti-F4/80 and
anti-CD206 antibodies. (×400 magnification and Scale bars = 50 μm). (E) Leukocytes were gated with CD45 fluorescence, macrophage M2
marker (CD45+F4/80+CD206+) were detected by flow from metastatic foci in the liver after intrasplenic injection of SL4 cells in WT and Cat S−/− mice.
Data are mean ± SEM for n = 8 mice per group. NS indicates not significant. **, P<0.01.
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associated LC3 (LC3 II) and free cytosolic LC3 (LC3-I)
by western blotting. As shown in Figure 4D, in control,
the LC3-II formation was in low level either WT or
Cat S−/− macrophages, no difference between the two
groups. Consistent with autophagic vesicle accumulation,
SL4 cells induced LC3-II formation in WT macrophages,
which was even further enhanced in Cat S−/− macrophages
(Figure 4D). Our results suggest that Cat S deficiency may
induce the accumulation of autophagosomes in macro-
phages with the tumor microenvironment.Cat S is required for autophagic flux of TAMs
The flux rate of autophagy can be controlled by several
steps: 1) the enclosure of cytoplasmic components by
phagophores to form autophagosomes; 2) the fusion of
autophagosomes with lysosomes to form autophagolyso-
somes; 3) the dissolution of autophagolysosomes [11,15].
To investigate whether Cat S is involved in the initi-
ation and progression of autophagy, autophagic flux
was assessed using colocalization analysis of the tandem
fluorescent mCherry-GFP-LC3 expression vector. In
autophagosomes, both GFP and mCherry fluorescence
Figure 4 Cat S deficiency increases accumulation of autophagosomes in macrophage in the tumor microenvironment. (A) Double
immunofluorescnce analysis of macrophage (anti-F4/80) and the autophagosome marker LC3 in metastatic foci from WT and Cat S−/− mice. The
sections were stained with anti-F4/80 (red) or anti- LC3 (green) antibody and DAPI (blue; to stain the nuclei). Scale bars = 10 μm. (B) Double
immunofluorescnce analysis of macrophage (anti-F4/80) and the autophagosome marker LC3 in WT or Cat S−/− macrophages cocultured with
SL4 cells for 48 hrs and serum-starved for at least 12 hrs before co-culture. The sections were stained with anti-F4/80 (red) or anti- LC3 (green)
antibody and DAPI (blue; to stain the nuclei). Scale bars = 40 μm. Three independent experiments were performed. (C) Ultrastructure was
detected by transmission electron microscopy in WT or Cat S−/− macrophages cocultured with SL4 cells for 48 hrs and serum-starved for at least
12 hrs before co-culture (×10000 magnification). Three independent experiments were performed. (D) Western blot analysis of LC3 protein
expression in WT or Cat S−/− macrophages cocultured with SL4 cells for 48 hrs and serum-starved for at least 12 hrs before co-culture. WT or Cat
S−/− macrophages cultured individually as control group. Quantitative analysis of LC3-II/LC3-I ratio in WT or Cat S−/− macrophages cocultured with
SL4 cells. Data are mean ± SEM of 3 independent experiments. **, P<0.01. NS indicates not significant.
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cence in the mCherry-GFP-LC3 fusion protein weakens
and eventually disappears under acidic pH, making it a
fluorescent sensor to simultaneously analyze autopha-
gosomes and autophagolysosomes [37]. Progression from
autophagosomes to autophagolysosomes, therefore, pre-
sents as less colocalization and stronger red fluorescence.
In Cat S−/− or WT macrophages, the lower basal level
of autophagy presented as low-intensity fluorescence
and was poorly localized (Figure 5A). We found that
mCherry-GFP-LC3 expression was detected as pre-
dominantly red and yellow spots rarely observed in
WT macrophages cocultured with SL4 cells, suggestingthat the expression is mainly associated with autophagoly-
sosomes (Figure 5A). In contrast, in Cat S−/− macrophages
cocultured with SL4 cells, yellow speckles with a higher
level of GFP and mCherry fluorescence and their colocali-
zation were significantly observed compared with those in
WT macrophages (Figure 5A, right panels). The inhibition
of fusion of autophagosomes with lysosomes resulted in the
accumulation of mCherry-GFP-LC3 on autophagosomes;
therefore, the number of GFP-LC3 puncta per cell was
substantially higher in Cat S−/− macrophages than in WT
macrophages cocultured with SL4 cells, with no differ-
ence between the two cell types at baseline (Figure 5B).
Our results indicated that Cat S deficiency inhibited
Figure 5 Cat S inhibition causes defective autophagy flux in macrophage in the tumor microenvironment. (A) WT or Cat S−/− macrophages
were transfected with Cherry-GFP-LC3, then cocultured with SL4 cells for 48 hrs and serum-starved for at least 12 hrs before co-culture. Confocal
fluorescence was used to image autophagosomes (red and green foci) and autolysosomes (red-only foci). Scale bars = 10 μm. Three independent
experiments were performed. (B) WT or Cat S−/− macrophages expressing the GFP-LC3 reporter construct were seeded in plastic wells, then
recognition and counting by fluorescence image analysis using the KineticScan HCS Reader. Data are mean ± SEM of 3 independent
experiments. **, P<0.01. NS indicates not significant. (C) WT or Cat S−/− macrophages were cocultured with SL4 cells and serum-starved for
at least 12 hrs before co-culture, and WT macrophages in the presence or absence of Cat S inhibitor Z-FL-COCHO (10 μmol/L). WT or Cat
S−/− macrophages were loaded with 10 μg/mL DQ-Green BSA for 15 min, washed twice and incubated in media for the indicated times,
then subjected to flow cytometry analysis. Background (gray peak) represents samples without the DQ-Green BSA loading. Three independent
experiments were performed. (D) WT or Cat S−/− macrophages were placed on coverslips as above in C, and incubated in media containing
DQ-Green BSA (10 μg/mL) for 15 min. Cells were washed twice with PBS and incubated in media for the indicated times. Cells were fixed and
the fluorescent degradation products of the DQ-Green BSA in lysosome were imaged using confocol images analysis. Scale bars = 5 μm. Dotted
lines indicate the cell margin. Three independent experiments were performed.
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flux rate in TAMs.
An increase in autophagy should coincide with enhanced
lysosomal activity and general proteolysis. We utilized
the self-quenched reporter substrate, DQTM Green BSA
(DQ-BSA) to measure of the cellular proteolytic/lysosomal
activity. DQ-BSA-green is a bovine serum albumin (BSA)
labeled with a self-quenching fluorescent dye. After DQ-
BSA-green is delivered to lysosomes via endocytosis, it is
hydrolyzed into single dye-labeled peptides by lysosomal
proteases, thereby relieving self-quenching, and the green
fluorescence can subsequently be monitored by flow cy-
tometry [38]. Thus, DQ-BSA is useful for detecting intra-
cellular proteolytic activity as a measure of a functional
lysosome. To further examined whether Cat S deficiencycould prevent autophagy flux, DQ Green BSA was pre-
loaded and dequenched in macrophages, and the rate
of disappearance of dequenched DQ-BSA was moni-
tored. As shown in Figure 5C, left panel, fluorescent
signals were decreased by approximately 90% over the
time period of 21 hrs in WT macrophages cocultured
with SL4 cells. However, in the presence of the Cat S
inhibitor Z-FL-COCHO, fluorescence peaks shifted to
the left was obviously inhibited, demonstrating that the
flux of dequenched DQ-BSA was significantly delayed
(Figure 5C, middle panel). Similarly, we observed the
loss of the fluorescent signals was markedly blocked in
Cat S−/− macrophages compared with that in WT mac-
rophages cocultured with SL4 cells, indicating that Cat
S deficiency attenuated the DQ-BSA degradation rate
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treated with the Cat S inhibitor or Cat S−/− macrophages
showed enlarged dequenched DQ-BSA-containing vesi-
cles (Figure 5D, top and bottom panels). These results
consistently suggested that Cat S is required for clearing
dequenched DQ-BSA or flux of amphisomes.
Cat S-mediated autophagy contributes to M2 phenotype
polarization of TAMs
To further confirm that Cat S-mediated autophagy
plays an important role in macrophage polarization in
the tumor microenvironment, we treated WT or Cat S−/−
macrophages with the autophagy inhibitor chloroquine
(CQ) prior to coculture with SL4 cells, and assayed the
expression of M2-type genes (arginase-1, Arg-1; found
in inflammatory zone protein, FIZZ1 and interleukin-10,
IL-10) and M1-type genes (inducible nitric oxide synthase,
iNOS; interleukin-1β, IL-1β and tumor necrosis factor-
α, TNF-α). As shown in Figure 6, coculture of SL4 cells
markedly upregulated the mRNA levels of Arg-1, FIZZ1
and IL-10 (M2-specific genes) in WT macrophages,
whereas CQ significantly inhibited the expression of Arg-1,
FIZZ1 and IL-10 in WT macrophages cocultured with SL4
cells. Moreover, coculture of SL4 cell induced a significant
increase in expression of Arg-1, FIZZ1 and IL-10 in WTFigure 6 Cat S is essential for macrophage autophagy contributing to M
were pretreated with 50 μmol/L autophagy inhibitor (Chloroquine, CQ)
serum-starved for at least 12 hrs before co-culture. Quantitative real-time PCR
marker (iNOS, IL-1β, TNF-α). Tubulin was a normalization control. Data are me
not significant. Mφ indicates macrophages.macrophages compared to that of Cat S−/− macrophages
(Figure 6). Importantly, CQ treatment did not alter the ex-
pression of Arg-1, FIZZ1 or IL-10 in Cat S−/− macrophages
cocultured with SL4 cells (Figure 6, top panels). In addition,
WT macrophages treated with CQ expressed higher
levels of iNOS, displaying an M1-skewed profile when
cocultured with SL4 cells (Figure 6). Cat S−/− macro-
phages also showed a marked increase in the expression
of iNOS compared with that in WT macrophages follow-
ing coculture with SL4 cells, and this profile was not fur-
ther altered in Cat S−/− macrophages with CQ treatment
(Figure 6, bottom panels). Taken together, Cat S-mediated
autophagy promotes the polarization of TAMs toward an
M2-like phenotype.
Discussion
TAMs represent a dominant myeloid population in many
solid tumors, and their accumulation correlates with poor
prognosis [7,33]. TAMs-secreted cathepsin protease activ-
ity has been implicated in the pathogenesis of cancer [30],
yet the mechanisms by it promotes tumor development
are incompletely understood. In this study, we identified
Cat S as the most abundantly expressed cysteine protease
of the cathepsins family in tumor-infiltrating macrophages,
and its level was associated with poor prognosis in human2-type polarization of macrophages.WT or Cat S−/− macrophages
or DMSO (vehicle) for 1 hr and then subjected to SL4 cells coculture,
analysis of the mRNA expression of M2 marker (Arg-1, FIZZ1, IL-10) or M1
an ± SEM of 3 independent experiments. *, P<0.05. **, P<0.01. NS indicates
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potentiator of tumor development through maintaining
macrophage cellular homeostasis and mediating the
switch to an M2 phenotype in TAMs. Moreover, we
gained further insights into the potential mechanisms
underlying Cat S as a critical mediator of autophagic flux,
the cancer-promoting function of TAMs.
Clinical studies have shown that Cat S is expressed in
95% of cases of primary colorectal tumors and their related
metastatic tissue, with significantly higher expression in
tumors compared with matched normal colonic mucosa
[39]. In vitro findings demonstrated that specific inhib-
ition of Cat S by an antibody, Fsn0503, could attenuate
colorectal cancer cell invasion [25]. Furthermore, these
effects were confirmed in a murine model of sporadic
pancreatic carcinogenesis (RIP1-Tag2), in which the genetic
ablation of Cat S severally inhibited tumorigenesis through
attenuation of tumor invasion and angiogenesis [23].
However, the mechanism by which stroma-derived Cat S
promotes tumor development remains unclear. Therefore,
in present investigation, we aimed to investigate the role
and the mechanism of Cat S in regulating tumor micro-
environment. In this study, we observed that colon carcin-
oma patients at more advanced clinical stages, those with
lymph node or liver involvement, or those who have had
recurrence within 3 years displayed markedly higher
Cat S expression levels (Figure 1B). These results indicate a
potential of Cat S as an independent or supplementary bio-
marker in the prediction of tumor prognosis. Furthermore,
we found development of metastasized tumors in the liver
and tumor growth of PancO2 cells were greatly inhibited
in Cat S −/− mice compared to WT littermates (Figure 2),
suggesting a critical role of TAMs Cat S expression in
contributing to tumor development.
Besides of colon cancer tissues, previous studies have
shown that significantly high levels of Cat S have been
reported in a range of tumors including glioma [28], as-
trocytoma [24], lung cancer [40], prostate cancer [41], he-
patocellular [27], and pancreatic carcinomas [42], revealing
a possible role for this enzyme in tumour growth and pro-
gression. Cat S activity is also present in astrocytoma cells
in vitro and the extracellular levels of activity were highest
in cultures derived from grade IV tumors [24]. Further-
more, tumor cells such as breast cancer cells, pancreatic or
colon cancer cells, express functional Cat S which has been
proposed to involve in invasiveness of cancer cells [43,44].
In addition to the production of Cat S by the tumor
cells, further analysis confirmed that TAMs produced
the protease as previously shown in the mouse models
for pancreatic cancer and breast cancer [23,30,45,46].
Several studies have shown that expression of Cat S by
tumour-infiltrating macrophages, could be an important
contributor during prostate cancer progression [41]. Re-
cent studies have demonstrated that both tumor cellsand tumor-associated macrophages can produce Cat S
within the microenvironment to promote neovasculariza-
tion and tumor growth [47]. In the present study, the data
showed that Cat S deficiency impaired tumor angiogenesis
in metastatic foci. Consistent with our results, Cat S null
mice exhibited impaired endothelial microvessel develop-
ment, suggesting a key role for this protease in angiogenesis
[25]. Similarly, Cat S is markedly up-regulated by endo-
thelial cells during tumour angiogenesis [27,42] and im-
portantly, in a murine pancreatic islet carcinoma model
(RIP1-Tag2), Cat S knockout mice have been shown to a
significant reduction in tumour-associated angiogenic
switching and neovascularisation [23]. Furthermore, the
Cat S inhibitory antibody, Fsn0503, blocks extracellular
proteolysis, inhibiting endothelial invasion and tube
formation into developing tumors [48]. Taken together,
reduced angiogenesis in Cat S deficient mice could also
partially contribute to impaired tumor develpoment.
Lysosomal cysteine proteinases are known to mediate
intracellular protein turnover, regulating the half-life of
proteins critical for normal cell function. Cat S is restricted
to lymphatic tissues and cells such as macrophages, indicat-
ing more specific roles in cell physiology [40,49,50]. Given
that macrophages are major participants in host inflamma-
tory responses, dysregulation of macrophage function may
lead to diseases including autoimmune disease and cancer
[3]. In the present study, we provide both in vitro and
in vivo evidence that Cat S is required for M2 polarization
and cancer-promoting functions of macrophages in the
tumor microenvironment.
Autophagy is upregulated in response to stress, including
growth factor and nutrient limitation, energy depletion,
and hypoxia [12,51]. As a cell-refreshing and metabolism-
supporting pathway, autophagy is required for the normal
operation of cellular and organismal physiology. There-
fore, through selective autophagy, the central metabolism
may be supported by different substrates to restore meta-
bolic and energy homeostasis, redox balance, and biomass
production. Thus, autophagy can enable stress adaptation,
maintenance of cellular fitness, and survival under differ-
ent stress conditions [14]. In advanced cancers, autophagy
can promote tumor progression by providing nutrients
during starvation [14,16,52]. These findings suggest that
autophagy inhibition, rather than stimulation, might be
beneficial in the treatment of advanced cancer. Given
the known importance of TAMs in cancer development
and progression, the response of tumors to autophagy
inhibition may also involve the immune system. One of
the most important functions of autophagy is to maintain
cellular energy under conditions of nutrient deprivation
and other forms of stress [15]. The present study estab-
lished a novel role of macrophage-secreted Cat S in the
proper execution of autophagy. We showed that Cat S
was required for efficient autophagic flux, based on the
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accumulation of autophagic vacuole-like structures and
multivesicles than WT macrophages by serum starvation
during SL4 cells coculture (Figure 4C). Moreover,
significant higher levels of LC3-II were detected in
Cat S-deficient macrophages than WT macrophages
(Figure 4D). Autophagy is a vacuolar lysosomal degradation
pathway for long-lived proteins and damaged organelles
that are critical for maintaining cell function under stress
conditions. During the late stage of autophagy, autophago-
somes are presented to lysosomes to degrade damaged
organelles (i.e., mitochondria) [12,53]. In the present study,
Cat S deficiency increased autophagosome formation in
macrophages in the tumor microenvironment (Figure 5A).
Furthermore, we also showed that Cat S was required for
the fusion processes of autophagosomes and lysosomes, as
there were significantly defects in the dequenching process
of DQ-BSA in Cat S inhibitor-treated macrophages and
Cat S-deficient macrophages cocultured with SL4 cells
(Figure 5C and D). These results suggest that the fusion
of the autophagic vacuole with the lysosome and the
subsequent degradation of its content by Cat S are crucial
for proper execution of autophagy in TAMs.
Macrophages are highly heterogeneous cells that can
be activated to a functional status between M1 and M2
phenotypes in response to environmental signals. In a
simplified view, macrophages activated by LPS and IFN-γ
are referred to as M1 macrophages, which are capable
of killing pathogens and tumor cells [4,5]. Macrophages
activated by IL-4, IL-13, and IL-10 are referred to as M2
macrophages, which can suppress inflammation, induce
angiogenesis, promote tissue repair, and enhance tumor
growth [4,5]. We demonstrated that the autophagy inhibi-
tor CQ impairs the transition toward the M2 phenotype
in macrophages within the tumor microenvironment.
Importantly, lack of Cat S and CQ treatment did not pro-
duce additive suppression of M2 macrophage transition
within the tumor microenvironment, further highlighting
the biological necessity of Cat S-mediated autophagy in
mediating M2-type polarization of TAMs.
Cat S, a cysteine protease of the papain family, is
expressed in lysosomal/endosomal compartments of
antigen-presenting cells, such as B cells, macrophages and
dendritic cells (DCs) [54]. Inside the B cells and DCs, Cat S
is the single enzyme during the assembly of the MHC class
II-α and II-β chains with the antigenic peptide in the lyso-
somal/endosomal compartments [55]. This process contrib-
utes to antigen-induced adaptive immunity. Moreover, Cat
S has been shown to dominate autoantigen processing in
human thymic dendritic cells, which would be an import-
ant factor that influences selection of autoreactive T cells
[56]. These findings suggest the role of Cat S in other
immune cells could potentially also invovle in changes
of our observed tumor development in this study.Conclusions
In summary, the activity of Cat S plays an important role in
macrophage autophagy in the tumor microenvironment,
leading to regulation of the M2 phenotype of TAMs. The
results of the present study provide a strategy to selectively
target inflammatory cells in combination with autophagy,
an approach that could have significant therapeutic poten-
tial. Thus, controlling the activity of Cat S involved in
autophagy, by developing drugs that target this process,
can be considered as a future antitumor strategy.
Materials and methods
Antibodies and reagents
The antibodies for CD68, Ki-67, CD31, Mac-2, GAPDH,
and IgG were from Santa Cruz Biotechnology (Santa
Cruz, CA); the antibodies for Cat S, F4/80 and LC-3 was
from Abcam (Cambridge, MA); and ChemMate TM
EnVision System/DAB Detection Kits were from Dako
(Glostrup, Denmark). Antibodies for PerCP/Cy5.5-
conjugated CD45.2, phycoerythrin (PE)-conjugated F4/80,
fluorescein isothiocyanate (FITC)-conjugated CD206
and isotype control were from Biolegend (San Diego, CA).
Cat S inhibitor, Z-FL-COCHO was purchased from
Calbiochem (San Diego, CA). Autophagy inhibitor,
Chloroquine were purchased from Sigma (St. Louis, MO).
Animals
The Cat S−/− mouse strain was backcrossed onto the
genetic background of C57BL/6 for more than 10 gen-
erations. Mice were 8–12 weeks old at the beginning of
the experiments, matched for age and sex with wild-type
(WT) mice, and kept under specific pathogen-free (SPF)
conditions at the Beijing Anzhen Hospital affiliated to the
Capital University of Medical Science, China. All animals
received humane care in compliance with the Animal
Management Rule of the Ministry of Health, People’s
Republic of China (documentation no. 55, 2001) and
the Care and Use of Laboratory Animals published by
the US National Institutes of Health (NIH Publication No.
85–23, revised 1996) and approved by the Institutional
Animal Care and Use and Committee of the Capital
University of Medical Science (Beijing, China).
Tumor model
PancO2 [57] and SL4 [32] cells are pancreatic and colon
cancer cells, respectively, derived from C57BL/6 mice on
the same background as the Cat S−/− mice and WT control
mice. PancO2 and SL4 cells were maintained in DMEM/
F12 culture medium, supplemented with 10% FBS in a
humidified 37°C incubator under 5% CO2.
For in vivo subcutaneous tumor model, PancO2 cells
were harvested and single-cell suspensions of 1.0 × 106
cells in 200 μl medium were injected subcutaneously
into the right flank. Mice were sacrificed 28 days after
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with a caliper using the formula: V = π × [d2× D]/6, where d
is the minor tumor axis and D is the major tumor axis. For
in vivo hepatic metastasis model, after anaesthetizing mice,
a transverse incision in the left flank was made, exposing
the spleen, 1.0 × 106 SL4 tumor cells in 100 μl DMEM/F12
medium were intrasplenically injected with use of a
26-gauge needle. 14 days after inoculation, mice were
sacrificed, and the tissues were processed as described
below. The spleen and liver were removed, wet spleen
and liver weights were measured, and the incidence of
liver metastasis was examined.
Human colon carcinoma specimens
The specimens from 30 cases of human colon carcinoma
tissue/adjacent normal colon tissues and the clinicopath-
ologic data were obtained from the Second Affiliated
Hospital to Nanchang University gastrointestinal tumor
bank. The specimens were isolated at the time of surgery,
formalin-fixed and paraffin-embedded, and stained with
hematoxylin and eosin, then examined by 2 experienced
pathologists. The clinicopathologic stage was deter-
mined according to the TNM classification system of the
International Union against Cancer. RNA was extracted
for fresh tissue specimens (from 15 colon carcinoma
specimens and 15 adjacent normal colon tissues) with
identifiable tumor in the tissue specimen. Human speci-
mens use for research had been approved by the Second
Affiliated Hospital to Nanchang University Research
Ethics Committee.
Histology and immunohistochemistry
Specimens were fixed for 24 hrs with 10% buffered formalin
before embedding in paraffin. Serial sections of 5 μm thick
were obtained for histologic analysis. Hematoxylin&eosin
(HE) staining involved standard procedures.
For immunohistochemistry, sections were incubated with
the primary antibodies for Cat S (1:200), CD68 (1:200),
Ki-67 (1:200), CD31 (1:200), Mac-2 (1:200), then incubated
with the Dako ChemMateTM EnVision System (Dako,
Glostrup, Denmark) for 30 min. Staining was visualized
with use of diaminobenzidine and counterstaining with
hematoxylin. Negative controls were omission of the pri-
mary antibody, non-immune IgG or secondary antibody
only; in all cases, negative controls showed insignificant
staining. The expressions of Cat S, CD68, Ki-67, CD31,
Mac-2 were calculated as proportion of positive area to
total tissue area for all measurements of the section.
For double immunofluorescence, 7 μm frozen tissue
sections were permeabilized and blocked with 0.1% Triton
X-100, 0.2% bovine serum albumin, and 5% normal donkey
serum in PBS, then incubated with the primary antibodies
F4/80 (1:100), LC-3 (1:200) and Cat S (1:200) overnight at
4°C, then FITC or TRITC-conjugated secondary antibody(Jackson Immuno Research Laboratories, West Grove,
PA, USA) at 4°C for 1 hr in the dark, and coverslipped
with DAPI-containing mounting medium.
RNA analysis
Total RNA were extracted by use of TRIZOL (Invitrogen,
Carlsbad, CA, US). For reverse transcription, 1 μg of total
RNA was used to generate first strand cDNA with Oligo-
dT primer. Real-time PCR was performed using the SYBR
Green Mix (Bio-Rad) on the CFX96 Real-time System
(Bio-Rad). The Table 1 shows the primer used.
Western blotting
Protein extracts were diluted with loading buffer and sepa-
rated by electrophoresis on 8%-10% SDS-polyacrylamide
gels before transfer to nitrocellulose membranes (Bio-Rad).
The membranes were blocked in Odyssey blocking buffer
(LI-COR Bioscience, Lincoln, NE) at room temperature
for 1 hr, then incubated at 4°C overnight with primary
antibodies: Cat S (1:1000), LC-3 (1:1000), GAPDH
(1:3000). The membranes were washed 3 times in TBST
and incubated with fluorescent secondary antibodies
(Alexa Fluor 680 or IRDye 800, Rockland Immunochemicals,
Gilbertsville, PA, US) for 1 hr at room temperature at
1:5000, blots were analyzed with the Odyssey infrared
imaging system and Odyssey software.
Flow Cytometry
The content of inflammatory cells was quantified by flow
cytometry as described [58]. Briefly, tumor tissues were
cut into multiple small cubes and digested in an enzyme
mixture for 45 mins at 37°C. The cell suspension was
centrifuged and pre-incubated with Fc-γ block antibody
(anti-mouse CD16/32; Pharmingen, San Diego, CA, USA)
to prevent nonspecific binding. Cell staining involved dif-
ferent combinations of fluorochrome-coupled antibodies
to CD45, F4/80, CD206 for 30 mins at 4°C in the dark.
Fluorescence data were collected by use of an EPICS XL
flow cytometer (Beckman Coulter) and analyzed by use of
Cellquest (Beckman). Fluorescence minus one (FMO)
controls were included to determine the level of non-
specific staining and auto-fluorescence associated with
subsets of cells in each fluorescence channel.
Co-cultures of bone marrow-derived macrophages
(BMDMs) and tumor cells
Co-culture systems were established by using transwell
inserts (0.4 mm pore, polycarbonate membrane; Costar,
Cambridge, USA) and transferred to 6-well culture plates.
Bone marrow-derived macrophages (BMDMs) were iso-
lated from tibias and femurs of 8-week-old wild-type
C57BL/6 or Cat S−/− mice as previously described [58].
SL4 cell suspensions (1 ml, 1 × 106 cells) were loaded in the
upper inserts, and WT or Cat S−/− BMDMs suspensions
Table 1 Primers used for qRT-PCR
Primer Forward Reverse
Human cathepsin B 5′gtttgcattgctggtcagga3′ 5′tggcaggacagtggaatgat3′
Human cathepsin D 5′gcgagtacatgatcccctgt3′ 5′ctctggggacagcttgtagc3′
Human cathepsin F 5′ tggcaacaagatgaagcaag3′ 5′ttttgtgacagcccccttac3′
Human cathepsin H 5′actggctgttgggtatggag3′ 5′ aggccacacatgttctttcc3′
Human cathepsin K 5′ccgcagtaatgacacccttt3′ 5′gcacccacagagctaaaagc3′
Human cathepsin L 5′acagtggaccaagtggaagg3′ 5′cttctcccacactgctctcc3′
Human cathepsin S 5′tcatacgatctgggcatgaa3′ 5′aggttctgggcactgagaga3′
Human cathepsin Z 5′aagggggtaatgacctgtcc3′ 5′ttcattgcatgtcccacatt3′
Human GAPDH 5′acagtcagccgcatcttctt3′ 5′acgaccaaatccgttgactc3′
Mouse Arg-1 5′aaagctggtctgctggaaaa3′ 5′ acagaccgtgggttcttcac3′
Mouse FIZZ1 5′ttgcaactgcctgtgcttac3′ 5′ctgggttctccacctcttca3′
Mouse IL-10 5′ccaagccttatcggaaatga3′ 5′ttttcacaggggagaaatcg3′
Mouse iNOS 5′gggctgtcacggagatca3′ 5′ccatgatggtcacattctgc3′
Mouse IL-1β 5′gcccatcctctgtgactcat3′ 5′aggccacaggtattttgtcg3′
Mouse TNF-α 5′tcttctcattcctgcttgtgg3′ 5′ggtctgggccatagaactga3′
Mouse Tubulin 5′tctaacccgttgctatcatgc3′ 5′gccatgttccaggcagtag3′
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; Arg-1, arginase-1; FIZZ1, found in inflammatory zone 1; IL-10, interleukin 10; iNOS, inducible NO synthase;
IL-1β, interleukin 1β; TNF-α, tumor necrosis factor-alpha.
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of the culture well for 48 hrs and serum-starved for at least
12 hrs before co-culture. Serum-free DMEM/F12 without
SL4 cell inserts was used as a control in the lower com-
partment of well. BMDMs were preincubated for 1 hr
with 10 μmol/L Cat S inhibitor Z-FL-COCHO or 50 μmol/L
autophagy inhibitor Chloroquine, immediately after SL4
cells plating and controls received equivalent dilution with
DMSO vehicle alone.
Transmission electron microscopy
For transmission electron microscopy (TEM), cells were
fixed in 2% glutaraldehyde in 0.1 M sodium cacodylate buf-
fer (pH 7.0) for 2 hrs, post-fixed in 2% osmium tetroxide
for 2 hrs and then rinsed with 0.1 M cacodylate buffer.
Cells were enrobed in 5% Noble Agar and washed with dis-
tilled water 5 times, further fixing with 2% uranyl acetate
for 2 hrs, followed by dehydration in 50% (15 min), 70%
(16 h), 85% (15 min), 95% (15 min), and 2 changes of 100%
ethanol each 15 min. They were then cleared by 2 changes
of propylene oxide, each 15 min, and infiltrated with epon
resin:propylene oxide (1:1) for 3 hrs, epon resin:propylene
oxide (3:1) for 16 hrs, and 2 changes with pure epon resin
for total 6 hrs. Thin sections were mounted on grids and
examined under the electron microscope (Philips EM410).
Autophagy flux assays
mCherry-GFP-LC3 transfection
Cat S−/− or WT BMDMs were transfected with mCherry-
GFP-LC3 reporter construct by using Lipofectamine 2000(Invitrogen, Carlsbad, CA) as previously described in our
lab [31]. After transfection, Cat S−/− or WT BMDMs
cocultured with SL4 cells without serum for 48 hrs. Cells
were fixed with 4% paraformaldehyde and microphoto-
graphs of mCherry-GFP-LC3 fluorescence were obtained
with the confocal laser-scanning microscope (TCS 4D;
Leica, Heidelberg, Germany). Treatment-induced changes
in GFP intensity in mCherry-positive puncta were calcu-
lated to depict autophagic flux.
High-throughput image analysis
Cat S−/− or WT BMDMs expressing GFP-LC3 were seeded
in 96-well plates, then cocultured with SL4 cells in 100 μl
of medium/well without serum for 48 hrs. Images data
were collected with an ArrayScan HCS 4.0 Reader with a
20× objective (Cellomics) for hoechst-labeled nuclei and
GFP-tagged LC3. The detection of punctated staining of
GFP-LC3 from the diffuse staining indicated the formation
of autophagosomes. Images of 1,000 cells for each well were
analyzed to obtain the average cell number per field, fluor-
escence spot number, area, and intensity per cell.
DQ-BSA degradation assays
To quantify protein degradation induced by stimuli, au-
tophagy flux was analyzed by flow cytometry and confocal
microscopy using the self-quenched substrate DQ-Green
BSA (Molecular Probes, Eugene, OR) as described in pre-
vious studies [59]. Briefly, WT or Cat S−/− BMDMs were
cocultured with SL4 cells for 48 hrs and serum-starved for
at least 12 hrs before co-culture. WT BMDMs were in the
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(10 μmol/L) cocultured with SL4 cells. WT or Cat S−/−
BMDMs into the lower compartment were loaded with
10 μg/ml DQ-Green BSA for 15 min at 37°C. The cells
were washed twice with PBS to remove excess label,
then harvested at indicated time points. Cells were har-
vested, and Green-fluorescent of DQ-BSA was analyzed
by flow cytometry using a FACSCalibur flow cytometer
(BD Biosciences) and CellQuest (BD Biosciences) and
FlowJo (Treestar) software. For confocal images analysis,
cells were placed on coverslips after treatment as above and
fixed with 4% formaldehyde. The fluorescent degradation
products of DQ-BSA in lysosomes were imaged using
a confocal laser-scanning microscope (TCS 4D; Leica,
Heidelberg, Germany).
Statistics
Data were analyzed with GraphPad Prism v5.00 for
Windows. Results are expressed as mean ± SEM. Differ-
ences were analyzed by t test or ANOVA, and results were
considered significant at a P<0.05.
Additional files
Additional file 1: Figure S1. Cat S deficiency inhibits angiogenesis in
tumor development. The area of vessels was evaluated by
immunohistochemical analysis with anti-CD31 antibody in PancO2
subcutaneous tumors (A) and in metastasized foci after intrasplenic
injection of SL4 cells (B). (×200 magnification and Scale bars = 100 μm).
Quantitative analysis of CD31 expression in subcutaneous tumors and
metastasized foci sections. Data are mean ± SEM for n = 8 mice with 10
fields per animal. **, P<0.01.
Additional file 2: Figure S2. SL4 cells induce Cat S expression in
macrophages. (A) BMDMs were cocultured with SL4 cells for 48 hrs
and serum-starved for at least 12 hrs before co-culture. Double
immunofluorescence analyses of Cat S expression in BMDMs with or
without SL4 cells treatment. BMDMs were stained with anti-F4/80 (red)
or anti-Cat S (green) antibody and DAPI (blue; to stain the nuclei).
(×400 magnification and Scale bars = 50 μm). Three independent
experiments were performed. (B) Western blot analysis of the protein
levels of Cat S in BMDMs with or without SL4 cells treatment. GAPDH
was used as a loading control. Quantitative analysis of Cat S/GAPDH
ratio in BMDMs with or without SL4 cells treatment. Data are mean
±SEM of 3 independent experiments. **, P<0.01.
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